Get notified regarding key financial metrics and revenue changes at Momenta PharmaceuticalsLearn more
Banner background

Summary - Funding Rounds

Founding Date

2001
Momenta Pharmaceuticals is a subsidiary of Johnson & Johnson

Momenta Pharmaceuticals Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

87.5m87.9m24.2m21.9m5.1m7.6m4.4m10.8m10.8m11.0m9.3m8.6m13.8m19.9m26.4m29.1m26.6m23.6m24.1m4.9m13.0m14.9m4.1m5.2m6.4m8.9m6.6m

R&D expense

14.2m16.3m18.6m20.0m20.2m22.3m22.0m27.4m26.7m26.1m27.5m22.7m34.0m31.7m28.8m33.2m31.6m36.1m39.1m37.9m33.2m31.3m30.7m28.0m32.1m46.1m34.2m

General and administrative expense

9.2m11.5m11.0m12.4m11.0m9.7m11.5m9.0m11.7m11.2m11.1m7.9m13.3m12.5m15.6m14.9m15.8m23.1m22.6m20.7m20.6m22.5m20.4m24.2m46.6m20.1m14.6m

Operating expense total

23.4m27.8m29.5m32.4m31.2m32.0m33.5m36.4m38.4m37.3m38.6m30.6m47.3m44.2m44.4m48.1m47.3m59.2m61.6m58.6m53.9m83.9m51.2m52.2m121.7m66.2m49.6m

EBIT

64.1m60.2m(5.3m)(10.5m)(26.1m)(24.4m)(29.1m)(25.7m)(27.6m)(26.4m)(29.3m)(22.1m)(2.4m)(30.4m)(24.6m)(21.6m)(18.2m)(32.6m)(38.1m)(34.5m)(49.0m)(70.8m)(51.8m)(48.1m)(116.6m)(46.1m)(40.7m)

EBIT margin, %

73%68%(22%)(48%)(512%)(322%)(668%)(239%)(256%)(241%)(314%)(258%)(220%)(124%)(82%)(62%)(122%)(161%)(143%)(1010%)(544%)(348%)(1169%)(2251%)(721%)(458%)

Interest expense

34.0k14.0k307.0k335.0k308.0k329.0k301.0k279.0k262.0k202.0k174.0k200.0k347.0k542.0k653.0k638.0k833.0k1.2m1.3m1.4m955.0k1.5m3.2m2.7m1.6m

Interest income

176.0k194.0k307.0k335.0k308.0k269.0k243.0k224.0k200.0k140.0k112.0k112.0k122.0k252.0k480.0k591.0k

Net Income

64.3m60.3m(5.0m)(10.2m)(25.8m)(24.1m)(28.8m)(25.4m)(27.4m)(26.2m)(29.1m)(21.9m)(2.2m)(30.0m)(24.0m)(21.0m)(17.5m)(31.8m)(36.9m)(33.2m)(47.6m)(69.9m)(50.3m)(44.8m)(114.0m)(44.5m)(39.6m)

Momenta Pharmaceuticals Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

23.9m70.5m38.7m68.3m84.9m43.3m26.5m37.1m45.5m62.9m54.9m97.6m271.8m70.0m89.4m88.2m106.3m260.5m110.8m172.8m88.2m82.4m65.2m131.2m123.5m122.1m179.7m191.1m

Accounts Receivable

84.8m84.7m22.4m19.4m5.0m5.4m3.1m6.4m7.8m8.6m7.6m5.9m33.7m11.1m16.6m6.6m

Prepaid Expenses

2.6m3.0m3.1m2.8m4.0m3.6m4.3m5.4m3.6m2.5m3.7m3.3m2.5m3.3m4.4m4.1m4.8m9.2m7.9m7.0m7.2m4.4m5.3m7.3m42.1m8.6m10.5m14.5m

Current Assets

336.4m398.3m426.3m413.1m371.9m334.5m309.1m293.0m239.1m215.9m190.9m210.7m415.8m391.2m371.9m376.9m359.5m469.5m481.6m442.5m338.3m328.5m294.2m346.3m317.1m286.1m490.4m457.4m

PP&E

11.1m11.6m20.3m22.3m23.3m21.4m22.4m24.4m25.3m25.8m24.9m23.9m22.8m22.4m21.5m21.8m21.0m21.4m23.9m29.9m31.5m31.9m29.5m15.1m11.8m11.6m11.2m10.8m

Total Assets

351.7m417.9m454.5m445.5m422.6m382.7m357.8m344.2m290.7m267.7m241.5m259.8m463.6m438.2m435.4m425.8m409.1m519.4m540.8m502.5m416.9m395.5m353.3m558.5m479.7m397.8m568.7m523.3m

Accounts Payable

3.2m2.6m9.4m3.8m6.7m3.6m2.8m6.2m4.9m4.0m3.2m5.5m1.9m5.7m3.4m12.1m9.8m7.1m12.1m12.7m6.0m8.5m4.6m9.3m10.4m3.5m2.5m4.7m

Short-term debt

650.0k551.0k2.9m3.2m3.5m4.0m4.2m

Current Liabilities

13.0m15.2m22.6m21.1m20.2m15.9m16.8m22.9m19.2m19.6m18.6m23.1m29.6m30.2m36.9m45.1m48.2m114.5m118.1m106.3m34.5m49.4m54.4m51.6m41.8m40.6m83.2m71.7m

Total Debt

650.0k551.0k2.9m3.2m3.5m4.0m4.2m4.5m5.0m5.3m5.6m6.1m6.4m6.6m7.2m7.8m8.1m8.7m9.0m

Total Liabilities

15.8m17.4m52.3m49.2m47.9m42.6m42.8m48.2m42.9m42.3m41.2m43.1m46.9m44.9m83.9m91.1m83.3m149.1m153.9m142.0m82.5m113.8m104.5m135.9m167.0m121.8m140.6m128.0m

Common Stock

5.0k5.0k5.0k5.0k5.0k5.0k5.0k5.0k5.0k5.0k5.0k5.0k7.0k6.0k7.0k7.0k7.0k7.0k8.0k8.0k8.0k8.0k8.0k10.0k10.0k10.0k12.0k12.0k

Preferred Stock

Additional Paid-in Capital

498.3m502.8m510.5m514.9m518.9m526.2m529.9m536.3m545.6m549.3m553.4m607.6m811.8m818.5m829.8m834.8m843.5m879.3m932.8m939.6m953.5m970.4m987.6m1.2b1.2b1.2b1.5b1.5b

Retained Earnings

(162.5m)(102.1m)(108.4m)(118.6m)(144.4m)(186.2m)(215.0m)(240.4m)(297.8m)(324.0m)(353.1m)(390.9m)(393.2m)(423.2m)(476.4m)(497.4m)(514.9m)(505.9m)(542.8m)(576.0m)(615.4m)(685.3m)(735.6m)(788.7m)(902.6m)(947.2m)(1.1b)(1.1b)

Total Equity

335.9m400.5m402.2m396.3m374.7m340.0m314.9m296.0m247.8m225.4m200.4m216.7m416.6m393.3m351.5m334.6m325.8m370.3m386.9m360.5m334.4m281.7m248.8m422.6m312.7m275.9m428.2m395.3m

Debt to Equity Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x

Financial Leverage

1 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.2 x1.2 x1.2 x1.2 x1.1 x1.1 x1.2 x1.3 x1.3 x1.4 x1.4 x1.4 x1.2 x1.4 x1.4 x1.3 x1.5 x1.4 x1.3 x1.3 x

Momenta Pharmaceuticals Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

121.3m181.6m(5.0m)(15.1m)(41.0m)(24.1m)(53.0m)(78.3m)(27.4m)(53.5m)(82.6m)(21.9m)(24.1m)(54.1m)(24.0m)(45.0m)(62.5m)(31.8m)(68.7m)(101.9m)(47.6m)(117.5m)(167.8m)(44.8m)(158.8m)(203.4m)(39.6m)(96.6m)

Depreciation and Amortization

2.2m3.1m1.3m3.4m5.4m1.8m3.6m5.3m2.1m4.2m6.5m2.4m4.5m6.6m2.2m3.8m5.7m1.3m3.0m5.6m2.1m4.3m6.4m6.1m10.6m11.7m1.0m2.1m

Accounts Receivable

(30.3m)(30.3m)5.8m8.8m23.2m5.4m7.7m4.4m5.3m4.5m5.4m1.6m(26.3m)(3.6m)

Accounts Payable

(1.2m)(1.8m)4.7m(867.0k)2.0m63.0k(829.0k)2.6m(1.5m)(2.3m)(3.2m)(1.9m)(5.5m)(1.7m)(665.0k)8.1m5.7m3.4m9.0m(5.6m)(2.8m)(5.9m)10.0k690.0k(5.8m)(11.7m)(9.4m)

Cash From Operating Activities

96.2m165.5m41.7m35.3m28.2m(15.6m)(36.3m)(60.0m)(20.2m)(39.2m)(64.1m)(28.6m)(44.6m)(47.2m)13.9m(8.8m)(36.2m)63.0m38.3m7.9m(38.2m)(75.0m)(121.4m)(37.6m)(111.3m)(166.8m)(64.6m)(105.7m)

Purchases of PP&E

(4.2m)(5.8m)(8.2m)(11.9m)(14.6m)(802.0k)(3.6m)(6.6m)(2.5m)(4.7m)(5.9m)(539.0k)(1.4m)(2.7m)(1.5m)(3.7m)(4.8m)(1.7m)(5.7m)(11.2m)(3.6m)(6.7m)(8.6m)(137.0k)(1.1m)(1.7m)(857.0k)(1.7m)

Cash From Investing Activities

(175.2m)(199.2m)(53.0m)(17.8m)5.3m5.0m8.5m39.7m34.1m70.4m86.6m28.3m22.9m(178.4m)13.5m36.0m80.8m27.3m(149.5m)(59.3m)44.4m60.6m81.5m(82.1m)(16.3m)683.0k(146.8m)(97.8m)

Long-term Borrowings

(1.1m)(1.2m)

Cash From Financing Activities

2.2m3.5m735.0k1.6m2.1m868.0k1.3m4.5m1.8m1.9m2.6m36.6m232.1m234.2m558.0k(438.0k)153.0k19.4m71.3m73.6m8.3m20.8m27.8m2.6m2.8m3.9m8.6m12.1m

Net Change in Cash

(76.8m)(30.2m)(10.6m)19.1m35.7m(9.7m)(26.5m)(15.9m)15.7m33.2m25.1m36.3m210.5m8.6m28.0m26.8m44.8m109.7m(39.9m)22.1m14.6m6.4m(12.1m)(117.1m)(124.8m)(162.3m)(202.8m)(191.4m)

Interest Paid

75.0k89.0k

Momenta Pharmaceuticals Ratios

USDQ2, 2011

Financial Leverage

1 x

Momenta Pharmaceuticals Employee Rating

4.162 votes
Culture & Values
3.8
Work/Life Balance
4.1
Senior Management
3.4
Salary & Benefits
3.8
Career Opportunities
3.5
Source